Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2019 | 12-2018 | |
| Cash Flows From Operating Activities | ||
| Net Income | -247 | 27 |
| Depreciation Amortization | 53 | 41 |
| Accounts receivable | 10 | 106 |
| Accounts payable and accrued liabilities | -31 | -464 |
| Other Working Capital | -24 | -341 |
| Other Operating Activity | 21 | 358 |
| Operating Cash Flow | $-217 | $-274 |
| Cash Flows From Investing Activities | ||
| PPE Investments | -13 | -40 |
| Purchase Of Investment | N/A | -12 |
| Investing Cash Flow | $-13 | $-52 |
| Cash Flows From Financing Activities | ||
| Debt Repayment | -17 | N/A |
| Common Stock Issued | -163 | 742 |
| Other Financing Activity | -1 | 1 |
| Financing Cash Flow | $-181 | $743 |
| Exchange Rate Effect | 10 | 4 |
| Beginning Cash Position | 1,260 | 839 |
| End Cash Position | 859 | 1,260 |
| Net Cash Flow | $-401 | $421 |
| Free Cash Flow | ||
| Operating Cash Flow | -217 | -274 |
| Capital Expenditure | -13 | -40 |
| Free Cash Flow | -230 | -314 |